ClinicalTrials.gg
RecruitingNCT07164378PERSPECTIVEUpdated Mar 20, 2026

International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study

An interventional study of Lens-Exchange and Add-on in Age - Related Macular Degeneration (AMD), sponsored by VisionCare, Inc.. Recruiting at 12 sites in 3 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by VisionCare, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Macular Degeneration by VisionCare, Inc. — 2 open to participants now, 3 under way, none of them phase 3. Macular Degeneration · VisionCare, Inc..

Planned enrollment
5th of 10
44 · median 31
Started
2025
the only one that year
No phase
9 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Macular Degeneration by VisionCare, Inc., this one is the 5th largest by planned enrollment, is the only one that started in 2025, is one of 9 with no phase, and was the 10th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 10 studies in Macular Degeneration by VisionCare, Inc. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Macular Degeneration by VisionCare, Inc., or all of them as a file.
02

Study summary

This study aims to expand the CE mark IFU of the SING IMT™ to pseudophakic (patients with an intraocular lents) patients with late stage of AMD (Age-Related Macular Degeneration) and bilateral central vision impairment. This randomized, international, multicenter study will evaluate the safety and efficacy of the device in this patient group. Findings will support regulatory submissions, clinical decision-making, and potential label expansion.

Read the detailed description

Eligible AMD patients with existing IOL on both eyes will be randomized to either have the SING-IMT device placed on top of the existing IOL, or to replace the existing IOL.

03

Conditions studied

  • Age - Related Macular Degeneration (AMD)

Keywords

  • Sulcus
  • AMD
  • Age-related Macular Degeneration
  • IOL
  • Intra-Ocular Lens
  • Pseudophakic
  • Samsara Vision
  • Add-on
  • SINGIMT
  • lens-exchange
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be 55 years of age or older;
  2. Subjects with late-stage AMD; Have retinal findings of geographic atrophy or disciform scar with foveal involvement in both eyes;
  3. Had cataract surgery (with IOL implantation in both eyes) at least 6 months prior to enrollment;
  4. BCDVA no better than 20/80 and no worse than 20/800 in both eyes.
  5. Have adequate peripheral vision in the eye not scheduled for surgery, assessed by observation of ambulation.
  6. Achieve using the ETS, at least 2-lines (10 or more letters) improvement in distance on the ETDRS chart in the eye scheduled for surgery.
  7. Have an Anterior chambre depth (ACD) of at least 2.5 mm, measured from endothelium, in both eyes.
  8. Have an ECD of at least 1600 cells per square mm in both eyes.
  9. Be willing to participate in a postoperative training program for the use of the SING IMT™ implant.
  10. Review and sign the IEC approved Form (ICF) prior to any clinical investigation-related procedures being performed.
  11. Patient is registered with the national social security or equivalent in the country where consent is signed
  12. A woman is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

13, Not a woman of (WOCBP): A WOCBP who agrees to follow guidance starting with the screening visit and through to the end of the study

Exclusion criteria

Exclusion Criteria:

A. Bilateral Ocular Conditions (affecting both eyes):

  1. Evidence of active choroidal neovascularization (CNV), or treatment for CNV within the past six (6) months.
  2. Diabetic retinopathy.
  3. Retinal vascular diseases.
  4. History of retinal detachment.
  5. Retinitis pigmentosa.
  6. Intraocular tumor.
  7. Corneal Stromal or Endothelial Dystrophies (for example corneal guttata)Corneal guttata.
  8. Patient predisposing to eye rubbing

    B. Surgical Eye Conditions:

  9. Narrow angle (i.e., \< Schaffer grade 2).
  10. Axial length \<21 mm or >26 mm.
  11. Any history or current ocular or intraocular inflammation, infection, or edema, including but not limited to: - Uveitis, iritis, keratitis, keratouveitis, microbial keratoconjunctivitis.
  12. Plate haptic shape IOL implanted.
  13. Vitrectomized eye.
  14. Zonular weakness, instability, presence of pseudoexfoliation.
  15. Iris abnormalities, including but not limited to: Transillumination defects (e.g., pigment dispersion syndrome), aniridia, iris neovascularization.
  16. Any IOL already implanted in the sulcus.
  17. Presence of toric or multifocal IOL types.
  18. Optic Nerve Disease

    C. Systemic or Other General Conditions:

  19. A history of -induced IOP elevation uncontrolled, glaucoma, or preoperative IOP >22 mmHg.
  20. Known sensitivity to post-operative medications.
  21. Significant communication impairment or severe neurological disorders.
  22. Administration of any product within 30 days prior to enrolment or planned participation in another clinical investigation during this study.
  23. Any condition or situation that, in the opinion of the investigator, may:

    • Put the subject at significant risk,
    • Confound the clinical investigation results, or
    • Interfere significantly with the subject's participation in the study.
  24. Individuals under legal care (e.g., incarcerated patients or those under legal guardianship) who are unable to understand and provide .
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Lens Exchange group

    SING IMT™ implantation in the sulcus after removal of the previously implanted IOL

    Procedure: Lens-Exchange

  • Experimental
    Add-On

    SING IMT™ implantation in the sulcus in front of an existing IOL

    Procedure: Add-on

Interventions

  • ProcedureLens-Exchange

    The existing IOL will be removed and replaced by implanting SING IMT™ device in the sulcus

  • ProcedureAdd-on

    The SING IMT™ device will be placed in front of the existing IOL and implanted in the sulcus.

06

What researchers measure

Primary outcomes

  1. percentage of ECD loss

    assessed within each treatment group relative to baseline (pre-surgery). The ECD loss should not exceed 23%

    Time frame: at baseline, then at 1, 3 and 6 months

Secondary outcomes

  1. Incision size required for device implantation

    measurement of the incision size

    Time frame: baseline

  2. Number of Surgical Complications, AEs and SAEs

    Assess number of safety events comparing to similar procedures.

    Time frame: at baseline, then at 1, 3 and 6 months

  3. Acuity

    Change in near and distance best corrected acuity in implanted eyes

    Time frame: at baseline, then at 1, 3 and 6 months

  4. Patient-reported outcomes

    Using the Impact of Vision Impairment (IVI) questionnaire, 28 questions are answered, providing 4 different scores: 1. Vision-related quality of life Average of all items (ranging from 0 to 2.9) 2. Reading and accessing information Average of (Q1, Q3, Q5, Q6, Q7, Q8, Q9, Q14, Q15), (ranging from 0 to 2.7) 3. Mobility and Independence Average of (Q2, Q4, Q10, Q11, Q12, Q13, Q16, Q17, Q18, Q19, Q20), (ranging from 0 to 3) 4. Emotional well-being Average of (Q21, Q22, Q23, Q24, Q25, Q26, Q27, Q28), (ranging from 0 to 3)

    Time frame: at baseline, then at 1, 3 and 6 months

07

Study locations

12 of 12 sites recruiting
  • Centre d'Ophtalmologie Paradis-Monticelli
    Marseille, France
    Recruiting
  • Hélios Ophtalmologie
    Saint-Jean-de-Luz, France
    Recruiting
  • CHU de Strasbourg
    Strasbourg, France
    Recruiting
  • Asklepios Augenklinik Nord-Heidberg
    Hamburg, Germany
    Recruiting
  • Augenklinik Sulzbach
    Sulzbach, Germany
    Recruiting
  • MVZ Augenklinik Petrisberg GmbH
    Trier, Germany
    Recruiting
  • Augenklinik und Poliklinik des Universitätsklinikums
    Würzburg, Germany
    Recruiting
  • Ospedale Generale Regionale "F. Miulli"
    Bari, Italy
    Recruiting
  • IRCCS Humanitas
    Bergamo, Italy
    Recruiting
  • Azienda Ospedaliero-Universitaria di Ferrara
    Ferrara, Italy
    Recruiting
  • Presidio Ospedaliero Palagi
    Florence, Italy
    Recruiting
  • Policlinico Universitario Fondazione Agostino Gemelli
    Roma, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 133 interventional studies with no phase under Macular Degeneration, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Sep 10, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Apr 30, 2027
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07164378
Lead sponsor
VisionCare, Inc.
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Sep 23, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Mar 20, 2026

Study contacts

Faustino Vidal Aroca
Contact
fvidalaroca@samsaravision.com
+39 3476255836
Waza Hadjebi
Contact
infos@centclin.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion